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Abstract
Malignant pleural mesothelioma (MPM) is an aggressive disease with a poor prognosis. Studies have shown that both MET
and its key downstream intracellular signaling partners, PI3K and mTOR, are overexpressed in MPM. Here we determined the
combinatorial therapeutic efficacy of a new generation small molecule inhibitor of MET, ARQ 197, and dual PI3K/mTOR
inhibitors NVP-BEZ235 and GDC-0980 in mesothelioma cell and mouse xenograft models. Cell viability results show that
mesothelioma cell lines were sensitive to ARQ 197, NVP-BEZ235 and GDC-0980 inhibitors. The combined use of ARQ 197
with either NVP-BEZ235 or GDC-0980, was synergistic (CI,1). Significant delay in wound healing was observed with ARQ
197 (p,0.001) with no added advantage of combining it with either NVP-BEZ235 or GDC-0980. ARQ 197 alone mainly
induced apoptosis (2062.36%) that was preceded by suppression of MAPK activity, while all the three suppressed cell cycle
progression. Both GDC-0980 and NVP-BEZ235 strongly inhibited activities of PI3K and mTOR as evidenced from the
phosphorylation status of AKT and S6 kinase. The above observation was further substantiated by the finding that a
majority of the MPM archival samples tested revealed highly active AKT. While the single use of ARQ 197 and GDC-0980
inhibited significantly the growth of MPM xenografts (p,0.05, p,0.001 respectively) in mice, the combination of the above
two drugs was highly synergistic (p,0.001). Our results suggest that the combined use of ARQ 197/NVP-BEZ235 and ARQ
197/GDC-0980 is far more effective than the use of the drugs singly in suppressing MPM tumor growth and motility and
therefore merit further translational studies.
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Introduction
Malignant pleural mesothelioma (MPM) is an aggressive tumor
originating in the serosal surfaces of the pleura, peritoneum,
pericardium, and tunica vaginalis [1]. MPM is diagnosed in about
3500 Americans each year; and its incidence is still increasing in
many areas of the world [2]. While the principal etiological factor
is exposure to asbestos, genetic predisposition, prior exposure to
Simian Virus 40 (SV40) and radiotherapy can trigger the
development of MPM [3–5]. The standard therapy for MPM is
combination chemotherapy with cisplatin and an anti-folate
analog [6,7]. Despite recent advances, this disease has a poor
prognosis and the median survival time is about one year [8],
clearly there is an urgent need for more efficacious therapeutics.
Receptor tyrosine kinases (RTKs) play a crucial role in tumor
growth and metastasis, providing key signals that lead to
transformation, proliferation and invasion [9]. Various studies
have shown that RTKs including epidermal growth factor
receptor (EGFR), MET, insulin growth factor receptor (IGFR)
and vascular endothelial growth factor receptor (VEGFR) are
expressed in MPM [10–14]. HGF (hepatocyte growth factor)/
MET signaling pathway is associated with acquired resistance to
EGFR inhibitors in EGFR mutant non–small cell lung cancers
[15]. It is therefore important to target MET along with a
complementary target that can potentially synergize to kill cancer
cells and ward off resistance.
We previously reported that MET is overexpressed and mutated
in a variety of malignancies including MPM [13]. Using several
mesothelioma cell lines, our group showed that the small molecule
MET inhibitor SU11274 suppresses cell proliferation. ARQ 197
(Tivantinib) is a non-ATP competitive inhibitor of MET that binds
to the non-phosphorylated inactive form of MET. Preclinical
studies show that ARQ 197 inhibits MET activation in multiple
cancer cell lines [16]. In this study, we determined the efficacy of
ARQ 197 in suppressing the growth of MPM cells and tumors.
A key downstream signaling molecule for MET and other
RTKs is phosphatidylinositol 39 kinase (PI3K), a cellular oncogene
and essential intracellular lipid kinase [17]. The p110a catalytic
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p85 are usually overexpressed and acquire frequent gain-of-
function mutations in MPM. The phosphatidyl-inositol-3,4,5-
trisphosphate (PIP3) generated by the PI3K at the cell membrane
recruits PH domain containing proteins such as PDK1 and AKT
to the plasma membrane resulting in activation of mTOR
complexes. The AKT and mTOR signaling cascades promote
cell proliferation and tumorigenesis. Therefore it is more effective
to simultaneously target both mTOR and PI3K. Several inhibitors
that target either PI3K alone or PI3K/mTOR are currently in
phase I cancer clinical trials [18].
GDC-0980 and NVP-BEZ235 are potent, orally bioavailable,
new generation small molecule dual inhibitors of class I isoforms of
PI3K and mTOR. Studies have shown that both NVP-BEZ235
and GDC-0980 significantly inhibit PI3K and mTOR activity,
and tumor growth in many preclinical cancer models. NVP-
BEZ235 and GDC-0980 are currently in phase I clinical trials in
patients with solid tumors [19–23].
Here we have determined the combinatorial efficacy of MET
inhibitor ARQ 197 and dual inhibitors of PI3K/mTOR in MPM.
Our studies clearly demonstrate that the combined use of ARQ
197 with GDC-0980 or NVP-BEZ235 results in significant
synergy in suppressing MPM cell proliferation and tumor growth.
Materials and Methods
Antibodies and Reagents
Antibodies for p110a, p-85, AKT, p-AKT
Thr308, p-AKT
ser473,
S6, p-S6
Ser235/236, cleaved PARP, total PARP, cyclin D1, p-MET
(1234/1235) and anti-MAPK antibodies (ERK and p-ERK) were
from Cell Signaling (Danvers, MA). Antibodies against total Met,
p-MET (pY1349 and pY1003) and Alexa Fluor Phalloidin 594
were from Invitrogen (Grand Island, NY). PIP3 antibody was from
MBL Co. Ltd (Japan). b-actin antibody was from Sigma (St. Louis,
MO).
Recombinant human HGF was from R&D Systems (Minneap-
olis, MN). Wortmannin and LY294002 were from Cell Signaling.
Crizotinib, GDC-0941, GDC-0980, ARQ 197 and NVP-BEZ235
were purchased from Selleck (Houston, TX). Stock solutions were
prepared in DMSO and stored at 220uC till further use.
Cell Lines
Seven human mesothelioma cell lines (H2596, H513, H2461,
H2052, H2452, H28 and H2373) and one nonmalignant
transformed mesothelioma control cell line (Met-5A) were
obtained from American Type Culture Collection (ATCC)
(Manassas, VA). All were cultured in RPMI 1640 medium
(Gibco/BRL) supplemented with 10% (v/v) fetal bovine serum
(FBS), L-glutamine and 1% penicillin-streptomycin at 37uC with
5% CO2. Met-5A cells were cultured in M199 media supple-
mented with various growth factors according to manufacturer’s
instructions (ATCC).
Cell Lysis and Immunoblotting
Cells were plated in 10 cm dishes in 10 ml RPMI and incubated
at 37uC. They were treated with indicated concentration of ARQ
197, NVP-BEZ235, GDC-0980 and combination of ARQ 197/
NVP-BEZ235 and ARQ 197/GDC-0980 for the time indicated.
Following treatment, whole cell lysates were prepared and proteins
were detected by immunoblotting as previously described [24].
Cell Viability
Exponentially growing cells were plated in 96 well flat bottom
plates in 10% FBS media for overnight. Next day they were
treated with the indicated drugs for 72 h. For each treatment eight
wells were used. The viability of cells was measured using Alamar
Blue method as described previously [24]. Values were normalized
to untreated controls to generate dose response curves. Each
experiment was repeated at least 3 times. IC50 values were
generated for all the cell lines using ‘Prism’ software.
Apoptosis Assay
H2596 cells were plated in 60 mm tissue culture plates
overnight. Next day the cells were treated with the indicated
drugs. After 48 h treatment, apoptosis was evaluated using
Annexin V apoptosis kit from BD Biosciences (San Jose, CA) as
per the manufacturer’s protocol.
Cell Cycle Analysis
H2596 cells were plated in 60 mm tissue culture plates
overnight. Next day the cells were treated with the indicated
drugs for 48 h. Cells were fixed in 70% ethanol in PBS, and stored
at 220uC for 24 h. Next day the cells were washed with cold PBS
twice and then resuspended in 300 ml of PBS containing RNase A
and incubated at 37uC for 1 h followed by the addition of
propidium iodide. Samples were analyzed by LSRII flow
cytometer (BD Bioscience). The percentage of cells in different
phases of the cell cycle was calculated by FloJo 9.3.0 software
(Tree Star Inc., Ashland, OR).
Tissue Microarrays (TMAs)
TMAs were assembled at the Brigham and Women’s hospital at
Boston, MA. The TMA had total 213 tumor samples, 196 normal
lung samples and 14 control samples. A minimum of three tissue
cores with a diameter of 1 mm was arrayed into a recipient block
using an automated tissue microarrayer ATA-27 (Beecher
Instruments, Sun Prairie, WI). All tissues were obtained under
protocols approved by applicable IRBs and they were used for
PTEN, and p-AKT staining. Tumor tissue immunohistochemistry
(IHC) staining was performed using standard techniques as
described previously [25]. All slides were reviewed by two
independent pathologists who were blinded to the identity of the
tissues. Two measurements, the percent and intensity of IHC
staining were used to evaluate the level of protein expression in a
tissue sample. The final IHC score was obtained by a semiquan-
titative method that accounts for staining intensity and percentage
of cells stained. Scoring of the immunostaining in the nuclei was
performed as follows: 0, no staining; 1+, weak staining; 2+,
moderate staining; and 3+, strong staining.
For IHC staining the p-AKT
Ser473 antibody (Cell signaling, cat.
# 4060) was diluted 1–20.
Mouse Histology and Immunohistochemistry
Paraffin embedded blocks of all tumor samples were cut at
5 mM and each sample was stained with Hematoxylin and Eosin
(H&E) for histologic analysis. IHC was done using CD31, MET,
p-MET and p-AKT antibodies as described previously [25]. All
samples were analyzed by scoring staining intensity.
Dot Blot Assay
Dot blot assay for PIP3 was performed as previously described
[26]. Briefly, cell lysates were prepared as described above and
50 mg was spotted directly onto a nitrocellulose membrane. The
membrane was blocked in 5% BSA in 0.05% Tween/TBS for one
hour at RT. The membrane was then incubated with the primary
PIP3 antibody (MBL Co. Ltd, Japan) at 1 mg/ml in BSA TBS/T
overnight at 4uC. The following day the membrane was washed
Role of MET and PI3K/mTOR in Mesothelioma
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proteins were visualized using an enhanced chemiluminescence
reagent (BIORAD, Hercules, CA). Densitometric analysis was
performed on the resulting images using Image J software (NIH,
Bethesda, MA).
Figure 1. Expression of p-AKT and PTEN in archival mesothelioma tumor tissue samples. Mesothelioma TMA containing 212 tumor
samples and 192 normal lung tissue samples probed with p-AKT and PTEN representative images are shown in (A). (B) Comparative average scores
of p-AKT and PTEN in TMA samples. (C) Representative immunoblot of mesothelioma cell lines for MET, p-110, p-85, Total AKT, p-AKT and loading
control b Actin.
doi:10.1371/journal.pone.0105919.g001
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The cells were treated with a single drug and also with a
combination of two drugs for 72 h. The synergy assay was done in
two steps. In step 1, non-constant ratio of combination of two
drugs was calculated by feeding the dose and effect data into
CompuSyn to calculate the combinational index (CI). In step 2,
the optimum ratio was selected from CI values, which is less than
one and drug concentration less than IC50 for both the drugs.
Using constant ratio, five different dose combinations of drugs
were tested. The dose and effect data was entered into CompuSyn
Figure 2. Effect of MET and PI3K/mTOR dual inhibitors on growth of human mesothelioma tumor cell lines. Met-5A, H2596, H513,
H2461 and H2052 were treated with ARQ 197, NVP-BEZ235, and GDC-0980 for 72 h at the indicated concentrations. Viability was measured by Alamar
Blue assay. The data shown represent the mean 6 SEM. (A) ARQ 197, (B) GDC-0980, (C) NVP-BEZ235, (D) Crizotinib.
doi:10.1371/journal.pone.0105919.g002
Table 1. IC50 of Mesothelioma cell lines with MET and PI3K/mTOR inhibitors.
ARQ 197 NVP-BEZ235 GDC-0941 GDC-0980 Crizotinib
Cell Line MET inhibitor PI3K/mTOR inhibitor PI3K inhibitor PI3K/mTOR inhibitor MET/ALK inhibitor
Met-5A 8.84 mM 29.39 nM No Effect 0.96 mM No Effect
H2596 0.11 mM 3.39 nM 0.66 mM 0.079 mM 0.48 mM
H513 0.25 mM 12.1 nM 0.62 mM 0.33 mM 0.47 mM
H2052 0.43 mM 13.86 nM 045 mM 0.27 mM 1.16 mM
H2461 0.16 mM 25.83 nM 1.35 mM 0.85 mM 2.91 mM
doi:10.1371/journal.pone.0105919.t001
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of synergy assay was done by the isobologram and combination-
index methods, derived from the median-effect principle of Chou
and Talalay using CompuSyn software (ComboSyn Inc.) [27].
Wound Healing Assay
Cells (7610
5) were plated in 10 cm tissue culture plates
overnight. Next day the cells were treated with the indicated
drugs for 24 h. They were then trypsinized and replated in 24 well
tissue culture plates containing cell culture inserts (Ibidi, Verona,
Figure 3. Synergistic anti-tumor activity of combination of ARQ 197 with NVP-BEZ235 and GDC-0980 in mesothelioma cell lines.
Cells were treated with ARQ 197, NVP-BEZ235 and GDC-0980 alone or in combination at serial concentrations for 72 h. Cell viability was measured by
Alamar Blue assay. Combination index (CI) plot analysis of ARQ 197/GDC-0980 and ARQ 197/NVP-BEZ235 combinations show that they interact
synergistically in H2596 and H513 cells. CI=1 shows additive effect, CI,1 is synergism and CI.1 is antagonism. Each experiment was carried out
independently and repeated at least three times. (A) CI plot of ARQ 197/BEZ235 in H2596 cells. (B) CI plot of ARQ 197/BEZ235 in H513 cells. (C) CI
plot of ARQ 197/GDC0980 in H2596 cells. (D) CI plot of ARQ 197/GDC0980 in H513 cells.
doi:10.1371/journal.pone.0105919.g003
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with PBS and the media was replaced. The fine scratch created by
the inserts was photographed at various time points and analyzed
by TScratch software (CSELab, ETH Zurich, Switzerland).
PamGene Assay
We used PamGene microarray technology (PamGene, Nether-
lands) to determine the activation status of various kinases. This
assay measures specific peptide phosphorylation by protein
kinases. The microarrays are embedded with 144 kinase-specific
peptide substrates per microarray, which allows multiplex
Figure 4. MET inhibition alone or in combination with PI3K/mTOR dual inhibitors suppresses cell motility. Wound healing assay was
performed in H513 and H2596 cells treated with ARQ 197(0.2 mM), GDC-0980 (0.2 mM), NVP-BEZ235 (60 nM) or combinations for 24 h as described in
the methods. Representative pictures of the degree of wound closure in control and treated (A) H513 and (B) H2596 cells at 12 h respectively. The
open wound at each time point was quantified and normalized to 0 h for (C) H513 and (D) H2596 cells. The experiments were repeated three times
in triplicate and average closure 6 SEM is shown.
doi:10.1371/journal.pone.0105919.g004
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were treated with ARQ 197, GDC-0980, NVP-BEZ235 alone and in combination for 48 h. Cell cycle profile was determined using flow cytometry after
staining with PI/RNase. Fig. A shows the percentage of cells in G1, S, and G2/M phases was quantified and the results expressed as the mean 6 SEM
of four independent experiments. H2596 (B) and H513 (C) cells, were treated with ARQ 197, GDC-0980, NVP-BEZ235 alone and in combination for
48 h. Cell lysates were prepared and immunoblotted for total PARP, cleaved PARP, cyclin D1 and actin as a loading control. H2596 cells treated with
ARQ 197, GDC-0980, NVP-BEZ235 alone and in combination for 48 h, the cells were then stained with Annexin V-FITC/PI and analyzed by flow
cytometry. Results are expressed as mean percentage of apoptotic cells 6 SEM of four independent experiments (D).
doi:10.1371/journal.pone.0105919.g005
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used to detect phosphorylation. The protocol was followed as per
manufacturer’s instructions. H513 cells were treated with indicat-
ed concentrations of ARQ 197 for 4 h and the lysates were
prepared as described above.
Xenograft Mouse Tumor Model for ARQ 197 and
GDC-0980
Female homozygous athymic nude mice aged 5-6 weeks from
Harlan Laboratories (Indianapolis, IN). Animal care was in
accordance with the Institutional animal care guidelines.
2.0610
6 H2596 mesothelioma cells were injected subcutaneously
in the right flank of each mouse. Tumor growth was measured
with calipers and volume (mm
3) calculated as (L 6 W 6 H)/2.
When the volume reached a mean of 200 mm
3, mice were
randomized into four groups (n=10 mice/group) to receive
vehicle alone, ARQ 197 alone (200 mg/kg), GDC-0980
(5 mg/kg) alone and a combination of ARQ 197 and GDC-
0980. Drugs were administered once a day for 4 weeks by oral
gavage. Body weight and tumor volume were recorded every 3
days until the study was terminated. Mice were sacrificed and
tumor tissues were excised and fixed in 10% buffered formalin and
embedded in paraffin.
Ethics Statement
The female homozygous athymic nude mice (5–6 weeks age)
were obtained and cared for according to institutional guidelines
under a protocol approved by the University of Chicago
Institutional Animal Care and Use Committee (Protocol number
ACUP 72035). The Human TMA samples were obtained under
The University of Chicago IRB protocol number 13473A-CR004
and Dana Farber Cancer Institute, Boston IRB protocol number
980-63. Tissue samples were obtained after informed consents
were signed.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism
version 5.0 (GraphPad Inc, San Diego, CA). In order to evaluate
statistically significant differences between two continuous vari-
ables the unpaired Student’s t-test was used. Differences were
considered significant when p#0.05.
Results
Expression of p-AKT and PTEN in Mesothelioma TMAs
In order to discern the activity of PI3K in MPM tumors, we
determined the phosphorylation status of its key substrate AKT
and the expression levels of its negative regulator PTEN in
archival mesothelioma tumor samples and their normal counter-
parts. A TMA of 213 MPM and 196 normal lung samples was
generated and IHC was performed. The expression of p-AKT was
significantly greater in tumor tissues than in matched normal
tissue, however there was no discernible difference in PTEN
expression (Fig. 1A, B). The above results suggested the presence
of highly active PI3K in MPM tumor tissues.
Expression of MET and PI3K/AKT in Mesothelioma Cell
Lines
Using a panel of seven MPM cell lines and Met-5A as control,
we determined the relative protein expression of p110a, p85, total
AKT, p-AKT and MET using whole cell lysates and immuno-
blotting. As shown in Fig. 1C, all of the mesothelioma cell lines
tested expressed varying but relatively higher levels of MET
compared to Met-5A. All the MPM cell lines expressed significant
but varying levels of PI3K (p85 and p110a) and AKT. H2373 and
the control cell line Met-5A expressed lower levels of AKT in
comparison to the other MPM cell lines examined. Taken
together, both MET and PI3K are expressed at increased levels
in the majority of MPM cell lines.
MET and PI3K/mTOR Inhibitors Significantly Suppress
MPM Cell Proliferation
Cell viability was determined in MPM and the Met-5A control
cells following treatment with increasing concentrations of ARQ
197, NVP-BEZ235 and GDC-0980 for 72 h. As shown in
Fig. 2A, cell viability was significantly decreased in all the
MPM cell lines in response to ARQ 197 but not in Met-5A.
The IC50s of ARQ 197 in MPM cell lines ranged from 0.1 to
0.4 mM in comparison, the IC50 for Met-5A was approximately
8 mM. We also tested the effect of crizotinib (Fig 2D), and the
IC50 values were slightly higher in all the MPM cell lines tested
compared to ARQ 197 (Table 1).
In the case of the PI3K/mTOR dual inhibitor GDC-0980, the
Met-5A cells demonstrated higher levels of cell viability (IC50
0.96 mM) in comparison to three out of the four MPM cell lines
tested. The IC50s for H2596, H2052 and H513 ranged from 0.08
to 0.3 mM. In comparison, H2461 (IC50 0.85 mM) behaved more
like the control cells (Fig. 2B).
On the other hand, all the five cell lines were sensitive to NVP-
BEZ235 and the IC50s ranged from 0.003 to 0.030 mM, with Met-
5A being the least sensitive (Fig. 2C). Table 1 is a summary of
IC50s values for all the treatments. We then determined the
efficacy of the combination of MET and PI3K/mTOR inhibitors
and limited ourselves to two MPM cell lines, H2596 and H513.
Effect of Combined Use of MET and PI3K/mTOR Dual
Inhibitors on Cell Viability
H2596 and H513 were treated with a combination of ARQ
197/GDC-0980 or NVP-BEZ235 for 72 h and the viability was
determined. The combination of ARQ 197/NVP-BEZ 235 had
significant synergistic effect on the suppression of the growth of
H513. The combination of ARQ 197/GDC-0980 on the other
hand showed greater synergistic effect in H2596 compared to
H513 cells in inhibiting cell growth. The synergy was calculated
using combination index plots. (Fig. 3A–D). Since MET signaling
is known to play an important and essential role in cell motility
and metastasis [28]; we next determined the effects of these drug
combinations on MPM cell motility.
Effect of Combined Use of MET and PI3K/mTOR Dual
Inhibitors on Cell Motility
The H2596 and H513 cells were treated with the indicated
drugs and their combinations for 24 h and scratch assay was
performed. Wound closure was documented over a period of 12 h
as shown (Fig. 4A, B). The open wound at each time point was
quantified and normalized to 0 h value (Fig. 4C, D). In both
H2596 and H513 cells, treatment with ARQ 197 alone was
sufficient to significantly suppress cell motility and delay wound
healing and there was no significant advantage to adding GDC-
0980 and NVP-BEZ235. This supports the notion that MET
signaling (independent of PI3K/mTOR) is a key contributor to
MPM cell motility [13].
Role of MET and PI3K/mTOR in Mesothelioma
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Inhibitors on Cell Cycle Arrest
To investigate the underlying mechanisms related to the loss of
viability and motility in MPM cells treated with MET and PI3K/
mTOR inhibitors, we determined the effect of these inhibitors on
cell cycle progression. H2596 cells were treated with the indicated
inhibitors for 48 h, and cell cycle phases were analyzed by flow
cytometry. Treatment of H2596 cells with either of the PI3K/
mTOR inhibitors, GDC-0980 or NVP-BEZ235 for 48 h signif-
icantly arrested the MPM cells in G0/G1 phase as compared to
the control group. On the contrary, treatment with ARQ 197
arrested the cells in G2/M phase. Interestingly, the combination
arrested the cells in G2/M but not G1 phase (Fig. 5A and Fig.
S1A, B,).
Effect of Combined Use of MET and PI3K/mTOR Inhibitors
on Apoptosis
Since growth arrest of cells, especially at G2/M phase can
trigger apoptosis [29], we next determined the levels of cyclin D1
and cleaved-poly (ADP-ribose) polymerase (PARP) in the treated
cells. The levels of cyclin D1, which is a G0/G1 cell cycle
regulator [30] were decreased in cells treated with ARQ 197,
GDC-0980 or NVP-BEZ235, in a dose dependent manner. In the
case of NVP-BEZ235 the effect was much more pronounced in
H513 cells compared to H2596 (Fig. 5B, C). However, the
combination of ARQ 197/GDC-0980 and ARQ 197/NVP-
BEZ235 induced the largest decrease in cyclin D1.
The combinatorial treatment of ARQ 197/GDC-0980 and
ARQ 197/NVP-BEZ235 however induced significant levels of
cleaved PARP in both MPM cell lines. Individual treatment with
GDC-0980 or NVP-BEZ235 had little effect as evidenced from
cleaved PARP levels (Fig. 5B, C). Similar results were obtained
via immunofluorescence staining of cleaved PARP (Fig. S2).
However ARQ 197 alone was extremely effective in the induction
of cleaved PARP in both MPM cell types, suggesting that MET
inhibition alone is sufficient to trigger apoptosis. We also
quantified apoptosis at 48 h of treatment with inhibitors using
Annexin V staining (Fig. 5D and Fig. S3A, B). There was a
four-fold increase in apoptosis detected via Annexin V staining in
H2596 cells treated with ARQ 197 that almost doubled with the
combinatorial treatment with GDC-0980. This effect was not
observed with NVP-BEZ235 (Fig. 5D).
Effect of MET Inhibition on Kinase Profiling using
PamGene Microarray
In order to establish that ARQ 197 indeed inhibited MET in
MPM cells and to identify other downstream targets, we treated
H513 cells with varying concentrations of ARQ 197 and subjected
the lysates to PamGene profiling. As expected, there was
significant inhibition of MET phosphorylation and surprisingly,
RON phosphorylation (Fig. 6A). The phosphorylation status of
MET downstream targets such as PI3K (p85), FAK and paxillin
also showed dose related decreases. To further confirm the
inhibition of phosphorylation of MET with treatment of ARQ 197
we treated the H513 and H2596 cells with varying concentrations
of ARQ 197 in the presence of HGF and subjected the lysates to
immunoblotting (Fig 6B). Here we have used three different p-
MET antibodies to check the phosphorylation status of MET.
With p-MET 1234/1235, there was a clear-cut inhibition in
phosphorylation of MET in H513 cells, but less so in H2596 cells.
Although with p-MET pY1349 and pY1003 antibodies results are
less significant, it showed the same trend in H513 cells. In H2596
cells the inhibition of p-MET was observed at the higher
concentration of ARQ 197. MAPK activity is known to mediate
cell motility, and promote viability and metastasis. Since ARQ 197
was the main suppressor of MPM cell motility and as combination
with PI3K/mTOR inhibitors had no added advantage, we also
determined the effect of ARQ 197 on MAPK activity in both
H2596 and H513 cells. HGF induced MAPK activity was
dramatically suppressed with the treatment of ARQ 197 (Fig 6B).
Effect of Combined Use of MET and PI3K/mTOR Inhibitors
on Downstream Signaling Pathways
H2596 and H513 cells were treated with increasing concentra-
tions of ARQ 197, or GDC-0980 or NVP-BEZ235 alone or in
combination (ARQ 197/GDC-0980 and ARQ 197/NVP-
BEZ235) for 4 h. Cell lysates were subjected to immunoblotting
and representative blots are shown (Fig. 7A, B). While AKT
phosphorylation (Ser
473, Thr308) was not significantly affected by
ARQ 197 treatment in either H2596 or H513 cells, the PI3K/
mTOR inhibitors NVP-BEZ235 and GDC-0980 had a dramatic
suppressive effect (Fig. 7A, B). The activation of ribosomal S6
kinase, that is immediately downstream of mTOR, was effectively
inhibited by both NVP-BEZ235 and GDC-0980; however ARQ
197 had a suppressive effect only at the highest concentration
tested in H513 but not in H2596 cells (Fig. 7A, B). Further, we
examined the levels of PIP3 the product of p110a in these cells
[17]. H2596 cells were incubated with ARQ 197, GDC-0980 or
NVP-BEZ235 alone or in combination (ARQ 197/GDC-0980
and ARQ 197/NVP-BEZ235) for 24 h. A representative dot blot
and accompanying densitometric analysis is shown (Fig. 7C). As
expected from the immunoblot results, ARQ 197 had a less
dramatic effect on PIP3 production compared to NVP-BEZ235 or
GDC-0980. GDC-0980 showed the largest inhibition of PIP3
production, even at low concentration (0.1 mM).
Taken together, the PI3K/mTOR inhibitors, more than ARQ
197 appear to efficiently suppress the growth providing signals
mediated through AKT and S6 kinase while ARQ 197 suppressed
cell motility and induced apoptosis.
Anti-MM Tumor Activity of MET and PI3K/mTOR
Inhibitors in a Mouse Xenograft Model
The antitumor activity of MET inhibitor ARQ 197 and PI3K/
mTOR inhibitor alone or in combination was further investigated
in a mouse xenograft model derived from H2596 cells. Mice were
treated daily by oral gavage with vehicle, ARQ 197, GDC-0980 or
their combination. The oral regimen started on 22nd day of MPM
cell xenograft, when tumors reached an average volume of
Figure 6. Effect of MET inhibitor ARQ 197 on kinase activation profile and downstream signaling pathways in MPM. The protein
tyrosine kinase activity profile obtained using H513 lysates treated with ARQ 197 as tested on PamChip microarrays. The color-coded response
signature (A) is shown as heatmap in which treatment related upregulation of kinase activity is shown by red and downregulation by blue. Protein
tyrosine kinase activity is down regulated in a dose dependent manner for most of the peptides. (B) H2596 and H513 cells were starved in 0.5% BSA
media for 16 to 18 h and then treated with ARQ 197 at indicated concentrations for 24 h. The cells were then stimulated with human recombinant
HGF (100 ng/ml) for 15 min before preparing the cell lysates. Immunobloting was then performed with the following antibodies Phospho-
MET
Y1234/1235, Phospho-MET
Y1003, Phospho-MET
Y1349, Phospho-Paxillin, Phospho-AKT
Ser473, Phospho -AKT
thr308, Phospho-ERK, phospho-S6K and the
corresponding total antibodies.
doi:10.1371/journal.pone.0105919.g006
Role of MET and PI3K/mTOR in Mesothelioma
PLOS ONE | www.plosone.org 10 September 2014 | Volume 9 | Issue 9 | e105919Role of MET and PI3K/mTOR in Mesothelioma
PLOS ONE | www.plosone.org 11 September 2014 | Volume 9 | Issue 9 | e105919200 mm
3. Although treatment with ARQ 197 or GDC-0980
alone inhibited tumor growth, the effect of GDC-0980 was far
greater than ARQ 197 (Fig. 8A, B). The vehicle control and
ARQ 197 group mice were sacrificed on day 19 due to higher
tumor burden and morbidity. Mice treated with GDC-0980 alone
or ARQ 197/GDC-0980 were sacrificed on day 28. The
combination of ARQ 197/GDC-0980 had a more significant
effect on suppression of tumor growth compared to any single drug
(p,0.001). The average tumor volume was less in mice treated
with ARQ 197/GDC-0980, followed GDC-0980 and ARQ 197
groups (Fig. 8A, B). The ARQ 197/GDC-0980 treated mice did
not suffer any body weight reduction, suggesting that the
combination of these two drugs was well tolerated (Fig. S4).
Tumor sections from vehicle control, ARQ 197, GDC-0980
and combination treated mice were immunostained with p-MET,
total MET, CD31 and p-AKT. We did not observe any significant
change in the expression of total MET and p-MET in all the
groups (data not shown). However there was a significant decrease
in p-AKT which is a key downstream signaling molecule of PI3K
and MET (Fig. 8C). CD31, an indicator of angiogenesis was also
decreased in the both MET and PI3K/mTOR inhibitor treated
mice as compared to vehicle treated mice (Fig. 8D).
Discussion
MPM is highly resistant to radiation therapy and the preferred
treatments are surgery (at early stages) and a combinatorial
treatment with cisplatin and pemetrexed [6,7]. The average
survival time after diagnosis is one year highlighting the pressing
need for the development of more effective therapies. Here we
have clearly demonstrated the benefit of combined targeting of the
RTK, MET and the key intracellular signal transducer, PI3K,
using in vitro and in vivo MPM xenograft models. As expected,
the MET inhibitor ARQ 197 and the PI3K/mTOR inhibitors
GDC-0980 and NVP-BEZ235 when used alone significantly
decreased MPM cell viability (Fig. 2A–D); however only ARQ
197 adversely affected the cell motility thereby indicating that
HGF/MET signaling promotes MPM cell motility independent of
the PI3K/mTOR pathway (Fig. 4A–D). The combination of
ARQ 197 with either GDC-0980 or NVP-BEZ235 had a strong
synergistic suppressive effect on MPM cell viability (Fig. 3A-D).
The underlying mechanism involved cell cycle arrest and
induction of apoptosis. While ARQ 197 induced cell cycle arrest
at G2/M phase, the PI3K/mTOR inhibitors induced G0/G1
arrest; the combination mainly caused accumulation of MPM cells
at G2/M. The MET inhibitor was a strong inducer of apoptosis in
MPM cells. ARQ 197, exhibited strong inhibition of MET
autophosphorylation (Y1234-1235) in H513 cells, but not in
H2596 cells. With two other p-MET antibodies the same trend
was found in H513 cells, but in the case of H2596 cells p-MET
inhibition was observed only at high doses. (Fig. 6 B). ARQ 197
also had a strong suppressive effect on HGF induced MAPK
activation (Fig. 6 B). The majority of the inhibitory effect on
downstream AKT and S6 kinases could be mostly attributed to the
two PI3K/mTOR inhibitors used. These findings were substan-
tiated by PamGene microarray analysis using ARQ 197. These
results showed that MET, as well as the related RON kinase, were
inhibited by ARQ 197 treatment. Also, the phosphorylation of
downstream targets such as the p85 subunit of PI3K, FAK and
paxillin were dampened. In addition, PI3K/mTOR inhibitors
were more effective in suppressing the phosphorylation of AKT
and S6 kinases and production of PIP3 compared to the MET
inhibitor. Finally, using a xenograft model, we demonstrated a
highly synergetic effect of combinatorial use of ARQ 197 with
GDC-0980 in the suppression of MPM tumor growth.
We previously showed that MET is overexpressed and active in
most of the MPM cell lines tested as well as in archival MPM
tissues. Here, we have shown that key MET downstream signaling
molecules including PI3K (p85 and p110a subunits), AKT and
phospho-AKT are also expressed in majority of the cell lines
tested. The archival human MPM tissue samples revealed
significant overexpression of p-AKT, an indication of activated
PI3K, a common feature shared by a variety of cancers [31–34].
In addition to overexpression of MET in MPM, we previously
identified mutations within the MET semaphorin domain (N375S,
M431V, and N454I), the juxtamembrane domain (T1010I and
G1085X), and an alternative spliced form exon 10 deletion. The
cell lines H513 and H2596 harbor the T1010I mutation and
exhibited the most dramatic reduction of cell growth when treated
with the MET inhibitor SU11274 [13]. Here we tested ARQ 197,
a non-ATP competitor of MET tyrosine kinase activity, reported
to suppress the growth of multiple cancer cell lines [16]. Cell
viability was decreased in all mesothelioma cell lines tested in
response to ARQ 197, with those harboring the T1010I MET
mutation (H513 and H2596) showing the greatest sensitivity.
The ability of ARQ 197 to specifically inhibit MET kinase
activity is controversial. Previous reports on ARQ 197 have shown
it to predominantly inhibit MET but not its related kinase RON
[16]. In vitro studies using purified MET indicated that ARQ 197
appeared to only bind to non-phosphorylated MET kinase domain
and prevented autophosphorylation in a time dependent manner
[35]. More recently other reports have emerged to challenge this
view. Studies using multiple cancer cell types have failed to detect
any inhibition of HGF-induced MET phosphorylation in ARQ
197 treated cells [36,37] although cell growth was still inhibited.
ARQ 197 was observed to disrupt microtubule assembly and
induce cell cycle arrest in these cells [36,37]. Unlike crizotinib and
PHA 665792, two MET ATP-competitive inhibitors, ARQ 197
inhibited the growth of both MET addicted and non-addicted
cancer cell lines [37]. Our studies using PamGene microarray
analysis revealed that ARQ 197 indeed targets MET in
mesothelioma cells; however it also inhibited RON (Fig. 6A).
The immunoblot analysis of the H513 and H2596 cells pretreated
with ARQ 197 and stimulated with HGF showed significant
inhibition of p-MET (1234/1235) in H513 cells, but less so in
H2596. Using other p-MET antibodies (pY1349 and pY1003) it
showed the same trend in H513 cells, and in H2596 it inhibited
phosphorylation of MET at higher concentration. In our hands,
ARQ 197 appeared to have no significant effect on EGFR activity
and EGFR is known to be overexpressed in MPM [38] (data not
shown). EPHB4, another prominent RTK expressed in MPM [39]
also appeared to be inhibited. FAK is a prominent downstream
kinase in MET signaling [40] and it’s phosphorylation is
suppressed by ARQ 197 in a dose dependent fashion (Fig. 6A).
Moreover, our data on the effect of ARQ 197 on cell viability is in
Figure 7. Effect of combined MET and PI3K/mTOR inhibition on kinase activation profile and downstream signaling pathways in
MPM. H2596 and H513 cells were plated in 10 cm tissue culture plates overnight and next day treated with indicated inhibitors for 4 h. Phospho-AKT
(p-AKT
Ser473, p-AKT
thr308), total AKT, p-S6K and total S6K were assessed in (A) H2596 and (B) H513 by immunoblotting. (C) H2596 cells were plated
in 10 cm tissue culture plates overnight and next day treated with indicated inhibitors for 24 h. PIP3 content was measured via dot blot and
densitometric analysis for each blot is shown.
doi:10.1371/journal.pone.0105919.g007
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inhibition of tumor growth. Results from tumor xenograft experiments testing the efficacy of ARQ 197 and GDC-0980 alone and/or combination
in inhibiting the growth of H2596 cell line tumors in nude mice. Oral gavage treatment with ARQ 197 (200 mg/kg/day) and/or GDC-0980 (5 mg/kg/
day) reduced H2596 tumor growth significantly relative to vehicle control (p,0.001). The combined use of ARQ 197/GDC-0980 was much more
effective than any single agent alone, in inhibiting the tumor growth (p,0.01). (A) Tumor sizes were recorded every three days till the end of the
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another MET kinase inhibitor, on MPM cell viability and growth
(4). In addition, that study also demonstrated that MET
knockdown using specific siRNA in MPM cells induced significant
apoptosis that mirrors our present finding that ARQ 197 also
induces apoptosis in MPM cells (Figure 5B–D). It is therefore our
contention that the effects of ARQ 197 seen on MPM cells are
mainly mediated through suppression of MET activity.
We have previously shown that the cytoskeletal adaptor protein
paxillin, a key MET downstream signaling molecule, plays a
significant positive role in lung tumor development [41]. Our
studies show that ARQ 197 inhibited phosphorylation of paxillin
thereby attesting to the ability of ARQ 197 to adversely affect the
cytoskeleton either through MET dependent or independent
pathways. Apart from paxillin, which mediates directional cell
motility, MAPK, a key intracellular signaling mediator and
transcription factor is also known to promote cell motility
[42,43]. Here we also demonstrated that treatment of H2596
and H513 MPM cells had a dramatic inhibitory effect on
suppression of HGF induced MAPK and paxillin phosphorylation
thereby explaining the underlying mechanism in ARQ 197
mediated suppression of cell motility seen in the above two
MPM cell lines.
PI3K signals impact cancer cell growth, survival, motility, and
the p110a is known to acquire gain-of-function mutations in
several cancers [44]. However, in the mesothelioma genomic
DNA extracts tested here, we did not detect any PI3K mutations
(data not shown). mTOR is a conserved PI3K-related ser/thr
kinase that plays a pivotal role in tumor growth as it funnels signals
from both receptors and nutrients to activate cell growth [45]. It is
upregulated in various cancers and may have a role in mediating
resistance to EGFR tyrosine kinase inhibition [46,47]. Our results
from the use of PI3K/mTOR dual inhibitor in MPM cells clearly
support the above contention and the downstream connections
between PI3K, AKT, mTOR and the ribosomal S6 kinase. The
ribosomal S6 kinase is placed downstream of mTOR. mTORC1
when activated induces phosphorylation of ribosomal S6 kinases
that then phosphorylates rS5. Due to the negative feedback loop
between S6K and IRS, simultaneously targeting PI3K and
mTOR kinases is a better approach than using inhibitors that
target either PI3K or mTOR alone. In the present study, we
initially determined the efficacy of PI3K first generation and
second-generation inhibitors such as wortmanin, LY294002 and
GDC-0941to curb MPM cell growth without much success (data
not shown) and therefore shifted the focus to PI3K/mTOR dual
inhibitors. GDC-0980 was reported to be a potent inhibitor of
breast, prostate and lung cancer cell growth and was much less
effective against melanoma and pancreatic cancers, most likely due
to the presence of highly active KRAS and BRAF usually
encountered in these cancers. GDC-0980 was shown to induce G1
cell cycle arrest followed by apoptosis in certain cancer cell lines.
Relatively low doses also inhibited xenograft tumor growth [23].
Both PI3K and mTOR dual inhibitors used here induced MPM
cells to accumulate in G0/G1 phase (Fig. 5A); and were not very
efficient at inducing PARP cleavage, a marker of apoptosis
(Fig. 5B, C). They were however, formidable inhibitors of in vitro
MPM cell growth and in vivo MPM xenograft tumor growth in
the nude mouse when combined with ARQ 197 (Fig. 8A, B).
NVP-BEZ235 yielded promising results against variety of cancers
[21,48–51]. It induced growth arrest in renal cell carcinoma cells
both in vitro and in vivo and was more effective compared to
Rapamycin, a TORC1 (mTOR) inhibitor [21]. Using glioma
cells, it was shown that NVP-BEZ235 specifically inhibited PI3K/
mTOR signaling; an observation supported by suppressed activity
of AKT, and S6K1. The cells also underwent autophagy and cell
cycle arrest at G0/G1 phase. In addition, there was a significant
anti-angiogenic effect as evidenced in mouse xenograft studies
[50]. The present studies are in complete accordance with the
above findings. For instance, both NVP-BEZ235 and GDC-0980
effectively suppressed AKT and S6K phosphorylation and
production of PIP3 in a dose dependent manner (Fig. 7 A, B,
C) and arrested MPM cells in G0/G1 phase (Fig. 5A, and Fig.
S1A, B).
It has been observed that inhibition of mTOR results in
enhanced cancer cell death [52]. In glioma cells, in addition to
inducing G0/G1 cell cycle arrest, NVP-BEZ235 was also observed
to enhance autophagy [51]. The efficacy of NVP-BEZ235 in
suppressing lung cancer cell growth was significantly enhanced by
combining it with chloroquine, an inhibitor of autophagy [51].
MET inhibition was also observed to enhance autophagy in gastric
adenoma cells [53]. In our hands, NVP-BEZ235 showed
significant synergy in killing MPM cells when combined with
ARQ 197 (Fig. 3A, B); however, we have not checked the status
of autophagy in these cells. GDC-0980 also showed significant
synergy in combination with ARQ 197 in MPM (Fig. 3C, D).
Several MET inhibitors are in various phases of cancer clinical
trials [54]; however no studies to date have been reported using a
combination of MET and PI3K inhibitors, especially in MPM. A
recent investigation reported significant synergistic inhibitory
effect on MPM cell growth with combined treatment of MEK
inhibitor U0126 and the PI3K inhibitor LY 294002 in vitro and in
vivo mouse models [33]. Based on our previous study and the data
presented here, we have shown that both MET and PI3K are
overexpressed in MPM [13,34]. Unlike other cancers [44], MPM
does not appear to undergo frequent gain of function mutations in
p110a (data not shown), however IHC analysis of archival MPM
tumor samples revealed overexpression of p-AKT that supports
the presence of highly active PI3K (Fig. 1A, B).
In summary, using MPM cell lines and a mouse xenograft
model, we have clearly demonstrated the advantage of the
combinatorial targeting of MET and PI3K/mTOR in MPM.
PI3K is a key downstream signaling molecule in the HGF/MET
pathway and significant synergy was observed when ARQ 197 was
combined with either GDC-0980 or NVP-BEZ235 in suppressing
MPM cell motility and growth and in vivo tumor development.
The observed synergy could be due to the fact that several RTKs,
apart from MET, are likely to be active in MPM that all feed into
the PI3K/mTOR pathway. Therefore, dual targeting MET and
PI3K/mTOR is logical. Our mouse study revealed a dramatic
suppressive effect of ARQ 197/GDC-0980 on in vivo MPM
tumor growth that is promising and warrants further translational
studies.
Supporting Information
Figure S1 MET inhibitor alone or in combination with
PI3K/mTOR dual inhibitors induces cell cycle arrest.
H2596 cells were treated with ARQ 197(0.2 mM), GDC-0980
experiment. (B) Representative images of mice and tumors treated with vehicle control, ARQ 197, GDC-0980 and their combination. (C)
Immunohistochemical staining of tumor tissues with total CD31 and p-AKT and quantification. Bar graphs indicate average expression with standard
error.
doi:10.1371/journal.pone.0105919.g008
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48 h. Cell cycle profile was determined using flow cytometry after
staining with PI/RNase, representative flow cytometry profiles are
shown in (A). The percentages of cells in G1, S, and G2/M phases
were quantified and the results expressed as the mean 6 SEM of
four independent experiments as shown in (B).
(TIF)
Figure S2 Effect of ARQ 197(MET inhibitor), GDC-0980,
BEZ 235 (PI3K/mTOR inhibitor) alone and in combina-
tion on cleaved PARP (Marker of apoptosis) in H2596
cells. H2596 cells were treated with ARQ 197(0.2 mM), GDC-
0980 (0.2 mM), NVP-BEZ235 (60 nM) alone and in combination
for 48 h. Cell were then fixed in 4% paraformaldehyde and
stained for cleaved PARP and actin as described in Methods S1.
(TIF)
Figure S3 Effect of ARQ 197, GDC-0980, NVP-BEZ235
alone and in combination on apoptosis of H2596 Cells.
H2596 cells treated with ARQ 197(0.2 mM), GDC-0980 (0.2 mM),
NVP-BEZ235 (60 nM) alone and in combination for 48 h as
indicated, the cells were then stained with Annexin V-FITC/PI
and analyzed by flow cytometry. Representative flow cytometry
profiles are shown (A). Results are expressed as mean percentage
of apoptotic cells 6 SEM of four independent experiments (B).
(TIF)
Figure S4 Mouse body weight during H2596 xenograft
and drug treatment. Mice were injected with H2596 cells on
the right flank and tumor growth was followed until the 22nd day
of MPM cell xenograft, when tumors reached an average volume
of 200 mm
3. Mice were then treated daily by oral gavage with
vehicle, ARQ 197, GDC-0980 or their combination and mouse
body weight was recorded every three days.
(TIF)
Methods S1 Immunofluorescence and Confocal Micros-
copy.
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